IQV

IQVIAC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

22%

Probability

Target price

$215.00

+19.0% vs current

Most likely

Base case

53%

Probability

Target price

$188.00

+4.1% vs current

B-

Bear case

25%

Probability

Target price

$150.00

-17.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-15

AI commentary

The verified primary-source tone is constructive on Q1 execution, EPS guidance, backlog, and repurchases, but forward visibility remains limited because the strongest company-specific test is backlog conversion over the next twelve months rather than an imminent discrete event. Trusted-news reaction was mixed around book-to-bill and demand durability, and no fresh analyst-revision evidence is available in the packet; this should therefore remain a cautious monitoring view.

RankAlpha Sentiment Codex - 2026-05-15

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-05-07eventExpanded buyback authorization adds capital-allocation supportMedium impact

On May 7, 2026 the board authorized an additional $2B of repurchases, lifting remaining authorization to $3.2B; this is a clear capital-allocation support point, but it is not enough by itself to resolve demand and leverage questions [#8-K-2026-05-07].

2026-12-31catalystFY2026 EPS guide raise needs confirmation through the rest of 2026Medium impact

IQVIA reported Q1 2026 revenue of $4.151B (+8.4% YoY), adjusted EPS of $2.90, Commercial Solutions growth of 11.6%, R&D Solutions growth of 6.2%, and raised full-year 2026 adjusted EPS guidance to $12.65-$12.95 while reaffirming revenue and EBITDA guidance [#10-Q-2026-05-05] [#IR-2026-05-05].

2027-03-31catalystR&D backlog conversion through March 2027 is the main company-specific forward testMedium impact

IQVIA reported R&D Solutions contracted backlog of $34.2B and said approximately $8.9B should convert to revenue over the next twelve months, up 7.6% year over year; conversion of that backlog, alongside 1.11x trailing-twelve-month book-to-bill, is the key forward evidence needed for a stronger rerating [#10-Q-2026-05-05] [#IR-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-15 • Updated nightlySource: Internal modelMethodology